ClinConnect ClinConnect Logo
Search / Trial NCT05598658

Effect of Remote Ischemic Conditioning on Cerebral Hemodynamics in Patients After Intravenous Thrombolysis (RICCH-IVT)

Launched by YI YANG · Oct 25, 2022

Trial Information

Current as of May 27, 2025

Completed

Keywords

Remote Ischemic Conditioning Intravenous Thrombolysis Cerebral Hemodynamics Cerebral Autoregulation Cerebral Blood Flow Velocity

ClinConnect Summary

In this study, cases of ischemic stroke who undergo intravenous thrombolysis within 4.5 hours from onset are included. The RIC group receive basic treatment and remote ischemic conditioning for 200mmHg at 6 and 18-24 hours after intravenous thrombolysis. The sham-RIC group receive basic treatment and remote ischemic conditioning for 60mmHg at 6 and 18-24 hours after intravenous thrombolysis. Both groups underwent cerebral hemodynamics after RIC and recorded the relevant indexes. The investigators aimed to determine the effect of remote ischemic conditioning on cerebral hemodynamics in patie...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. age ≥ 18 and \< 80 years, both sexes;
  • 2. a clear clinical diagnosis of acute ischemic stroke and treatment with standard rt-PA (0.9 mg/kg) IVT within 4.5 h of stroke onset;
  • 3. pre-onset modified Rankin Scale (mRS) score ≤1;
  • 4. baseline National Institute of Health Stroke Scale (NIHSS) score ≥5 and ≤25;
  • 5. Glasgow Coma Scale score ≥8.
  • Exclusion Criteria:
  • 1. having received bridging therapy (IVT plus mechanical thrombectomy);
  • 2. previous history of atrial fibrillation or electrocardiographic evidence of atrial fibrillation;
  • 3. contraindications to RIC treatment or previous RIC treatment or similar treatment;
  • 4. pregnancy or breastfeeding;
  • 5. life expectancy of ≤3 months or inability to complete the study for other reasons;
  • 6. unwillingness to be followed up or poor treatment compliance or participation in other clinical studies;
  • 7. had insufficient bilateral temporal bone windows for insonation of the middle cerebral artery.

About Yi Yang

Yi Yang is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative drug development. With a focus on collaboration and scientific rigor, Yi Yang specializes in designing and managing clinical trials across various therapeutic areas, ensuring compliance with regulatory standards and ethical guidelines. The organization is committed to fostering partnerships with healthcare professionals and institutions to facilitate the timely delivery of safe and effective treatments. Through a patient-centered approach and a robust operational framework, Yi Yang strives to contribute to the advancement of healthcare and the well-being of communities globally.

Locations

Changchun, Jilin, China

Changchun, Jilin, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials